{"preliminary_commentary":{"by_channel":{"x_thread":21,"podcast":5,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04093167\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"CRI-CCTG-002","nct_id":"NCT04093167","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cri-cctg-002-nct04093167. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Pembrolizumab alone","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Pembrolizumab + standard platinum-based chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Cancer Research Institute, New York City","Personal Genome Diagnostics","Mark Foundation for Cancer Research"],"completion_date":{"date":"2027-07-30","type":"ESTIMATED"},"conditions":["Lung Cancer"],"enrollment":{"count":53,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-31","lead_sponsor":"Canadian Cancer Trials Group","official_title":"A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Stage 1: Concordance rate between molecular response and radiologic response","timeFrame":"18 months"},{"measure":"Stage 2: Phase II Progression-Free Survival (PFS)","timeFrame":"3 years"},{"measure":"Stage 2: Phase III Overall Survival","timeFrame":"3 years"}],"references":[{"citation":"Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023 Oct;29(10):2559-2569. doi: 10.1038/s41591-023-02598-9. Epub 2023 Oct 9.","pmid":"37814061","type":"DERIVED"}],"start_date":{"date":"2020-05-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04093167"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cri-cctg-002-nct04093167"}